Efficacy and safety of novel anticoagulants in the elderly

Nikolaos Karamichalakis, Stamatis Georgopoulos, Konstantinos Vlachos, Ioannis Liatakis, Michael Efremidis, Antonios Sideris, Konstantinos P Letsas

Laboratory of Cardiac Electrophysiology, “Evangelismos” General Hospital of Athens, Greece

Abstract

Atrial fibrillation and venous thromboembolism (VTE) are common disorders associated with maleficient thrombotic events, particularly in the elderly patients. Polypharmacy, co-morbidities, and altered pharmacokinetics, often present in these patients, render the use of anticoagulants quite challenging. Novel oral anticoagulants (NOACs) have recently emerged as alternatives to Vitamin K Antagonists (VKAs) and are gradually increasing their popularity mainly because of their fewer drug and food interactions and ease of use. Their effectiveness and safety has been well-established in the general population but the balance between benefit and harm in the elderly is still unclear. Routine use in these patients is uncommon. Accumulating data have shown that the benefit of NOACs is consistent among all age groups, featuring equal or greater efficacy in preventing thrombotic events. Excess bleedings were lower with NOACs in comparison to VKAs, but bleeding patterns were disparate among them and head to head comparison is not available. The present review highlights on the efficacy and safety of novel anticoagulants in the elderly population.

Keywords: Atrial fibrillation; Efficacy; Novel oral anticoagulants; Safety; Venous thromboembolism

1 Introduction

Aging is regarded as a significant risk factor for atrial fibrillation (AF) and venous thromboembolism (VTE).\(^\text{[1,2]}\) AF is the most common cardiac arrhythmia, its prevalence increases with age and has been proven to be a critical risk factor for stroke.\(^\text{[3]}\) In the CHA\(_2\)DS\(_2\)-VASc score, a well-established stroke risk stratification scheme, patients of age 75 and older acquire two points to a maximum score of 9.\(^\text{[4]}\) The remaining risk factors of this score such as heart failure, hypertension, prior stroke, and diabetes mellitus are often present in the elderly patient.\(^\text{[4]}\) Likewise, VTE often emerges with the passing of time.\(^\text{[2,5]}\) After the age of 40, the risk for developing VTE approximately doubles with every decade.\(^\text{[6,7]}\) Thrombotic events associated with AF and VTE are common and the prognosis in the elderly can be severe, thus the urge for anticoagulant therapy is of utmost importance.\(^\text{[8-10]}\)

Until 2009, the group of vitamin K antagonists (VKAs), mainly warfarin, was the single option for anticoagulant therapy. Even though VKAs’ efficacy in preventing thrombotic events is well-established, their use in the elderly so far has been limited.\(^\text{[11-13]}\) Drug and food interactions, increased risk of bleeding and the need for routine monitoring are the main reasons that VKAs are insufficiently used in the older patients.\(^\text{[14,15]}\) Advanced age specifically is an accessional risk factor for major bleeding events when VKAs are used.\(^\text{[16]}\) Nonetheless, even when VKAs are prescribed, their response to the elderly varies and target international normalized ratio is often difficult to achieve and maintain.\(^\text{[14,15]}\)

Recently, four new oral anticoagulants (NOACs) have been released for prevention of thromboembolic complications in AF and VTE. These new anticoagulants dose-dependently inhibit either thrombin (Dabigatran) or factor Xa (Rivaroxaban, Apixaban and Edoxaban).\(^\text{[17]}\) Their main advantages over VKAs are fewer drug and food interactions, rapid onset and offset of therapeutic action plus they don’t require dose-level monitoring.\(^\text{[17]}\) In the general population, each of them has been proven to be at least as effective and safe as warfarin for reducing the risk for stroke and systemic embolism (SE) in AF, as well as the risk for recurrence of VTE.\(^\text{[18-25]}\)

2 Use of NOACs in elderly patients

Even though there are several studies in the general
population regarding the efficacy and safety of NOACs, no randomized controlled trial that involves only elderly patients, has been conducted yet.[26] As shown in Table 1, the mean age and percentage of participants ≥ 75 years old varies in the pivotal studies of NOACs (RE-LY for dabigatran, ROCKET-AF for rivaroxaban, ARISTOTLE for apixaban and ENGAGE-AF TIMI 48 for edoxaban).[18–21,27]

Because of predisposing factors such as high frequency of renal failure, low body mass index, differed body composition of muscle and fatty issue in the elderly, there are several concerns about the use of NOACs in this subgroup of patients.[16,28,29] Comorbidities and polypharmacy, often present in the elderly, are additional factors that raise these concerns.[16,28,29] Moreover, occasional reports suggested that NOACs are related to a higher potential risk of bleeding in the elderly.[30,31]

So far, there have been 11 studies including data about the safety and efficacy of NOACs in the elderly (Tables 2 & 3).[16-25,32-42] Recent reviews and meta-analyses demonstrate at least equal efficacy compared to VKAs in reducing thromboembolic events associated with AF and VTE.[26,27,43]

### Table 1. Mean age and percentage of participants ≥ 75 years old in pivotal studies of NOACs.

|       | RE-LY[18] | ROCKET-AF[19] | ARISTOTLE[20] | ENGAGE AF-TIMI 48[21] |
|-------|-----------|---------------|---------------|------------------------|
|       | Dabigatran | Rivaroxaban   | Apixaban      | Edoxaban               |
| D150 mg | (n = 6076) | (n = 6015)    | (n = 6022)    | (n = 7131)             |
| D110 mg | (n = 670)  | (n = 6015)    | (n = 6022)    | (n = 7131)             |
| W      | (n = 713)  | (n = 7133)    | (n = 7133)    | (n = 9120)             |
| R      | (n = 9081) | (n = 9081)    | (n = 9081)    | (n = 7035)             |
| W      | (n = 9081) | (n = 9081)    | (n = 9081)    | (n = 7036)             |
| Age (years) | 71.5 ± 8.8 | 71.4 ± 8.6 | 71.6 ± 8.6 | 73 (65–78) |
| ≥75 yrs | 40%        | 38%          | 39%          | 43%                    |
|        | 43%        | 43%          | 31%          | 41%                    |
|        | 40%        | 40%          | 40%          | 40%                    |

A: apixaban; D: dabigatran; E: edoxaban; NOACs: new oral anticoagulants; R: rivaroxaban; W: warfarin.

Their benefit is consistent across all the age-groups examined, including that of the elderly.[26,27,43,44] Likewise bleeding risks seem to be similar between NOACs and warfarin.[26,27,43,45] However, bleeding patterns that were noticed showed significant heterogeneity between dabigatran, rivaroxaban, apixaban and edoxaban. No head to head comparison is available so far on this issue.[26]

#### 2.1 Dabigatran

As featured in the RE-LY and RECOVER trials, dabigatran has been at least as effective as VKAs in the prevention of stroke/SE in AF and recurrence of VTE respectively.[18,22,26,27,39,43,45] Its efficacy has been observed across all age groups.[26,27,43,45] Dabigatran in the dose of 150 mg twice daily has been related to a significant reduction in stroke or SE compared to warfarin.[18,26,45] The latter superiority was not observed in the dosage 110 mg (b.i.d.), where on the corresponding rate was similar to warfarin.[26,43,45]

Risk for major bleedings seems to be similar between dabigatran 110 mg (b.i.d.) and warfarin in the elderly, while data have shown that dabigatran 150 mg (b.i.d.) is associated with a non-significant higher risk of major bleeding in this age-group.[26,45] Dabigatran 150 mg (b.i.d.) has also been related to an increased number of gastrointestinal bleedings in comparison to VKAs.[26,27,45] On the other hand, the risk of intracranial bleeding was significantly lower when dabigatran was used regardless of dose and age.[26,27,45]

Considering renal insufficiency is common in older patients and dabigatran’s almost 80% renal clearance, it is important that renal function must be monitored more frequently in these patients, when dabigatran is prescribed.[46] In any case, dabigatran is contraindicated in patients with creatinine clearance (CrCl) < 30 mL/min. The European medicines agency (EMA) suggests that 150 mg (b.i.d.) should not be administered to patients of age ≥ 80 years and should instead follow the 110 mg twice daily route. That limitation is not applicable by the US Food and drug Association (FDA).[46]

http://www.jgc301.com; jgc@mail.sciencep.com | Journal of Geriatric Cardiology
2.2 Rivaroxaban

ROCKET-AF trial has demonstrated that rivaroxaban is as effective and safe as warfarin for stroke prevention (ischemic or haemorrhagic), featuring no significant differences among the rates of ischemic strokes and major bleedings across all age groups.\[19\] Halperin, et al.,\[47\] in a later meta-analysis of ROCKET-AF trial, gathering data of participants ≥ 75 years old, found no significant interaction between age and the overall study outcomes. Studies including elderly patients indicate that rivaroxaban is non-inferior to warfarin in secondary prevention of VTE.\[23,26,43\]

Recent meta-analyses have shown that rivaroxaban is superior compared to conventional therapy in fatal and intracranial bleeding, although gastrointestinal bleedings seem to be more often with rivaroxaban in the elderly.\[26,45\] Rivaroxaban 20 mg is administered once daily, preferably with the evening meal. Dose adjustment is not required in older patients, but those with CrCl 15–49mL/min should receive 15 mg (o.d.).\[48\]

2.3 Apixaban

Data from studies with elderly participants have shown that apixaban is more effective than warfarin in reduction of stroke/SE and not-inferior in managing recurrence of VTE.\[26,27,43,44\] A sub-analysis of the ARISTOTLE trial has proven that the efficacy and safety of apixaban is consistent among various groups of patients, as categorized by the CHADS\(_2\), CHA\(_2\)DS\(_2\)-VASc and HAS-BLED scores.\[46\]

Apixaban has been related to a significant reduction in major and clinical relevant bleedings in the elderly, as well as in intracranial haemorrhages compared to VKAs.\[26,43,45\] The benefits of apixaban in bleedings reduction seem to apply similarly in older patients with renal impairment.\[50\] However, there are not sufficient data yet available concerning gastrointestinal bleedings when apixaban is used in elderly patients.\[26\]

Apixaban is administered 5 mg twice daily, unless two or more of the following characteristics are present: age ≥ 80 years, body weight ≤ 60 kg and serum Creatinine ≥ 1.5 mg/dL (133 \(\mu\)mol/L). In that case the recommended dosage according to EMA/FDA is 2.5 mg (b.i.d.).

2.4 Edoxaban

Edoxaban is the latest NOAC that has received FDA/EMA approval, thus data regarding its use in the elderly are restricted. ENGAGE AF-TIMI 48 trial has shown that edoxaban in both 60 and 30 mg (o.d.) is as effective as warfarin in prevention of stroke/SE.\[21\] Edoxaban 60 mg (o.d.) was superior in comparison to 30 mg (o.d.) in stroke/SE prevention.\[21\] On the other hand, the 30 mg edoxaban treatment was related to a reduced risk of gastrointestinal bleeding and all-cause mortality compared to warfarin.\[21\] Outcomes of the study were consistent among all agegroups including the elderly.\[26,45\] In the Hokusai-VTE trial, 1104 patients ≥ 75 years old were studied among a total of 8292 participants and edoxaban was proven to be non-inferior in the treatment of symptomatic VTE compared to warfarin.\[25\] The FDA does not suggest age-dose adjustment for edoxaban, though patients with impaired renal function (CrCl: 15–50 mL/min) should receive the 30 mg regimen.

3 NOACs in the elderly: challenges and practical considerations

Considering bleedings, major or minor, are common in the elderly, preventive measures must be examined\[14,45,51\] Such measures should include limited use of alcohol and drugs that enhance bleeding, such as antiplatelets, steroids or NSAIDs.\[45,51,52\] Blood pressure control is important and renal function must be monitored more often, specifically when dabigatran is prescribed.\[45,51,52\] Older patients receiving antithrombotic therapy, conventional or contemporary should generally avoid surgery, unless the necessity is absolute.\[45\]

Quite recently, idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.\[53,54\] Studies including patients with life-threatening bleeding or in need of invasive procedures or emergency surgery have shown that it completely and rapidly reverses the anticoagulant effects of dabigatran in most of the participants.\[55–57\] However, the studies that have been conducted included mainly healthy volunteers and the clinical experience in the elderly is limited.\[54,56,57\] Idarucizumab has been approved by the FDA/EMA and is now available in the United States and Europe. Until now, no reversal agent is available for the anticoagulant effects of Rivaroxaban, Apixaban and Edoxaban.

Considering the enhanced risk of bleeding and related comorbidities in the elderly patients, an individualized case-by-case approach should be chosen, instead of a generalized “one drug fits all” approach. Modern medicine focuses on individualized treatment, rather than disease-oriented care. Physicians should follow a more personalised strategy that matches the particular NOAC to the particular patient, taking into consideration each and specific patient/drug characteristic.
4 Conclusions

Increasing life-expectancy brings forward older patients that were mostly neglected and under treated in the past. Elderly patients with AF and VTE are at elevated risk of thromboembolic events and bleeding compared to younger patients. NOACs slowly but surely increase their popularity among all age groups due to fewer drug/food interactions, rapid onset/offset of action and ease of use, without routine monitoring necessary. Recent studies and meta-analyses have shown that their efficacy and safety are largely preserved in older patients. However, because of other comorbidities such as renal insufficiency, low body weight and polypharmacy, physicians should proceed cautiously. Individual potential risk, benefit and harness of treatment must be carefully examined before matching a NOAC to a particular patient. Further research is required, including prospective, randomized controlled trials of NOACs concentrating in older adults and head to head comparison.

References

1 Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110: 1042–1046.
2 Kyrle PA, Eichinger S. Clinical scores to predict recurrence risk of venous thromboembolism. Thromb Haemost 2012; 108: 1061–1064.
3 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983–988.
4 Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263–272.
5 Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost 2010; 8: 2105–2112.
6 Anderson FA Jr., Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107(23 Suppl 1): S9–S16.
7 Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol 2010; 56: 1–7.
8 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857–867.
9 Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493–503.
10 Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297–305.
11 Hylek EM, D’Antonio J, Evans-Molina C, et al. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006; 37: 1075–1080.
12 Deplanque D, Leys D, Parnetti L, et al. Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol 2004; 57: 798–806.
13 Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131: 927–934.
14 Gattellari M, Worthington J, Zwar N, Middleton S. Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians. Stroke 2008; 39: 227–230.
15 Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004; 126: 1938–1945.
16 Hutton BA, Lensing AW, Kraaijenhagen RA, Prins MH. Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs Aging 1999; 14: 303–312.
17 Harder S, Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol 2013; 69: 1617–1633.
18 Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.
19 Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891.
20 Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–992.
21 Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093–2104.
22 Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342–2352.
23 Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499–2510.
24 Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799–808.
25 Buller HR, Decousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406–1415.
26 Sharma M, Cornelius VR, Patel JP, et al. Efficacy and harms
of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation 2015; 132: 194–204.

Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955–962.

Jacobs JM, Stessman J. New anticoagulant drugs among elderly patients is caution necessary?: Comment on “The use of dabigatran in elderly patients”. Arch Intern Med 2011; 171: 1287–1288.

Karamichalakis N, Letsas KP, Vlachos K, et al. Managing atrial fibrillation in the very elderly patient: challenges and solutions. Vasc Health Risk Manag 2015; 11: 555–562.

Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366: 864–866.

Wychowski MK, Koidules PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 2012; 46: e10.

Ingelheims B. A dose response study of dabigatran etexilate (BIBR 1048) in pharmacodynamics and safety in patients with non-valvular atrial fibrillation in comparison to Warfarin, 2010. Http://clinicaltrials.gov/ct2/show/NCT01136408 (accessed February 14, 2016).

Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007; 100: 1419–1426.

Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation—the J-ROCKET AF study. Circ J 2012; 76: 2104–2111.

Ogawa S, Shinhara Y, Kannuri K. Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. The ARISTOTLE-J study. Circ J 2011; 75: 1852–1859.

Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010; 104: 633–641.

Chung N, Jeon HK, Lien LM, et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost 2011; 105: 535–544.

Yamashita T, Koresutne Y, Yasaka M, et al. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ J 2012; 76: 1840–1847.

Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129: 764–772.

Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008; 112: 2242–2247.

Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287–1297.

Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6: 1313–1318.

Sardar P, Chatterjee S, Chaudhari S, Lip GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc 2014; 62: 857–864.

Liu GI, Wang YF, Chen PY, et al. The efficacy and safety of novel oral anticoagulants for the preventive treatment in atrial fibrillation patients: a systematic review and meta-analysis. Drug Deliv 2014; 21: 436–452.

Andreotti F, Rocca B, Hust S, et al. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2015; 36: 3238–3249.

Huisman MV, Lip GY, Diener HC, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838–847.

Halperin JL, Hankey GJ, Woldyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa Inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 2014; 130: 138–146.

Bayer Pharmas. Xarelto® (rivaroxaban) [prescribing information], 2011. Http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf#zoom=100 (accessed February 20, 2016).

Lopes RD, Al-Khatib SM, Wallentin L, et al. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet 2012; 380: 1749–1758.

Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33: 2821–2830.

Hanou O, Assayag P, Belmin J, et al. Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. Arch Cardiovasc Dis 2013; 106: 303–323.

Yates SW. Novel oral anticoagulants for stroke prevention in atrial fibrillation: a focus on the older patient. Int J Gen Med 2013; 6: 167–180.
53 Pollack CV Jr., Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. *N Engl J Med* 2015; 373: 511–520.
54 Eikelboom JW, Quinlan DJ, van Ryn J, Weitz JI. Idarucizumab: the antidote for reversal of Dabigatran. *Circulation* 2015; 132: 2412–2422.
55 Thibault N, Morrill AM, Willett KC. Idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review. *Am J Ther*. Published online first: May 12, 2016. DOI: 10.1097/MJT.0000000000000460.
56 Pollack CV Jr., Reilly PA, Bernstein R, et al. Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. *Thromb Haemost* 2015; 114: 198–205.
57 Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. *Lancet* 2015; 386: 680–690.